Search | CATIE - Canada's source for HIV and hepatitis C information

Jump to Navigation Jump to Content

Sort Results

Filter by Programming

Health care delivery (1)

Filter by Specific Population

Filter by Topic

Filter by Infection

HIV (remove)
Hepatitis C (1)

Filter by Resource Category

Search results

Current filters: HIV drugs, HIV

164 search results

3
4
5
6
7

Agencies issue caution about use of dolutegravir by pregnant HIV-positive women: 2018, CATIE
Research summary - Webpage
Symtuza approved in Canada for treatment of HIV: 2018, CATIE
Research summary - Webpage
Dutch study ties HIV to erection problems in middle-aged men: 2018, CATIE
Research summary - Webpage
Winnipeg doctors use dolutegravir and darunavir for simplifying treatment: 2018, CATIE
Research summary - Webpage
Preliminary results of dolutegravir + 3TC for initial therapy of HIV: From TreatmentUpdate 224
2018, CATIE
Research summary - Webpage
Dolutegravir + 3TC as maintenance therapy—a pilot study: From TreatmentUpdate 224
2018, CATIE
Research summary - Webpage
Dolutegravir + rilpivirine as maintenance therapy: From TreatmentUpdate 224
2018, CATIE
Research summary - Webpage
The re-emergence of dual therapy: From TreatmentUpdate 224
2018, CATIE
Research summary - Webpage
What’s next for long-acting HIV drugs?: From TreatmentUpdate 222
2017, CATIE
Research summary - Webpage
Long-acting drugs for HIV: From TreatmentUpdate 222
2017, CATIE
Research summary - Webpage

3
4
5
6
7

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.

Please note that some content on this website contains language, information and images related to sexuality and drug use, and may not be intended for people of all ages. CATIE ensures that these resources, developed to help prevent the transmission of HIV, hepatitis C and other infections, are written and reviewed by health experts for content accuracy.